ELVNEnliven Therapeutics, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$25M

Net Income

-$20M

EPS (Diluted)

$-0.32

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$491M

Total Liabilities

$15M

Stockholders' Equity

$476M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$25M	-$27M	+7.3%
Net Income	-$20M	-$23M	+13.0%

ELVN Q3 2025 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena